| Identification | Back Directory | [Name]
Carbonic acid, [[(6aS,14R)-11,12-difluoro-3,5,6,6a,7,8-hexahydro-6-methyl-3,5-dioxo-14-phenyl-14H-pyrido[1',2':1,6][1,2,4]triazino[3,2-d][1,5]benzoxazocin-4-yl]oxy]methyl methyl ester | [CAS]
2741952-35-0 | [Synonyms]
Cap-dependent endonuclease-IN-21
Carbonic acid, [[(6aS,14R)-11,12-difluoro-3,5,6,6a,7,8-hexahydro-6-methyl-3,5-dioxo-14-phenyl-14H-pyrido[1',2':1,6][1,2,4]triazino[3,2-d][1,5]benzoxazocin-4-yl]oxy]methyl methyl ester | [Molecular Formula]
C26H23F2N3O7 | [MOL File]
2741952-35-0.mol | [Molecular Weight]
527.48 |
| Hazard Information | Back Directory | [Uses]
Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-21 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-21 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8B or 8A)[1]. | [References]
[1] Shuhui Chen, et al. Fused ring derivatives and their pharmaceutical applications. Patent WO2021233302A1. |
|
|